SUCCIPRO: Redefining the Future of Intestinal Health Through Innovation
10 FINALIST - II Entrepreneurship Call 2025: Women in Technology
When Virginia Fradejas founded SUCCIPRO in Barcelona, she wasn’t just launching a biotech startup, she was challenging one of the most persistent barriers in modern medicine: the lack of effective, safe, and accessible treatments for chronic inflammatory diseases like Crohn’s disease.
Today, SUCCIPRO stands as one of the most promising emerging companies in the field of technologies for sustainable development, and a shining example of how science, purpose, and innovation can converge to transform lives.
A Problem Too Big to Ignore
Crohn’s disease is more than a diagnosis, it is a daily battle.
Millions of people worldwide live with chronic pain, inflammation, and unpredictable flare-ups. And despite decades of research, half of patients still do not respond to advanced therapies. Those who do often face severe side effects linked to immunosuppressive drugs.
But what if the key to treating the disease didn’t lie in suppressing the immune system but in addressing the root metabolic imbalance driving the inflammation?
This is where SUCCIPRO’s story begins.
The Hidden Player: Succinic Acid
Scientists have long known that succinic acid, a naturally occurring metabolite, plays a crucial role in intestinal health.
Yet, no therapy had ever been designed to directly and selectively target this metabolite.
Until SUCCIPRO.
A First-in-Class Solution: SD1253
SUCCIPRO developed SD1253, an oral therapy uniquely designed to stay within the intestine and precisely modulate succinate levels.
It represents a completely new therapeutic approach:
No immunosuppression.
No systemic exposure.
No compromise between efficacy and safety.
Designed using advanced in silico tools and artificial intelligence, the therapy restores microbiome balance, calms inflammation, and helps prevent fibrosis, addressing several underlying mechanisms at once.
It is not just another drug.
It is the beginning of a new therapeutic category.
Why This Matters
Isabel Huber founder of SUCCIPRO
A Vision Rooted in Impact
What sets SUCCIPRO apart is not only its scientific rigor, but also its mission-driven approach.
The team behind the project experts in clinical research, endocrinology, biotechnology, and business development shares a common goal: introducing safer, smarter, and more sustainable solutions for global health.
Their work also positions Spain as a growing force in biomedical innovation, proving that world-changing therapies can emerge from local research ecosystems.
For patients who have exhausted their options, SUCCIPRO represents hope grounded in solid science.
In the following photograph, we see Sonia Fernández Veledo, co-founder of Succipro.
SD1253 has the potential to improve the lives of millions by:
offering a safer alternative to current treatments
reducing infections and severe side effects
providing a targeted and personalized approach through biomarker monitoring
expanding in the future to other conditions related to succinate imbalance, such as ulcerative colitis, metabolic disorders, and even certain cancers.
SUCCIPRO is not simply developing a therapy
It is paving the way for a future where medicine is:
more precise, not more aggressive,
more accessible, not more invasive,
more human-centered, not just symptom-focused.
In the photograph, we see Joan Vendrell, co-founder of Succipro.
More Than a Startup, A Movement
Virginia’s vision shows what happens when a scientist becomes an innovator and when innovation becomes purpose.
We are delighted to celebrate Succipro, awarded fourth place in the Women in Technology II Entrepreneurship Call 2025 by Tara for Women.
Congratulations to the incredible team your dedication, vision, and innovative approach inspire us all, and we can’t wait to see the meaningful impact your journey will create!